Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Haupt Pharma Wuelfing GmbH
EIR
•Haupt Pharma Wuelfing GmbH•December 7, 2018

Haupt Pharma Wuelfing GmbH – FDA EIR, Dec 7, 2018

Record Details

An FDA routine surveillance Good Manufacturing Practice (GMP) inspection of Aenova Haupt Pharma Wulfing GmbH, located in Gronau (Leine), Germany, was conducted from November 29 to December 7, 2018. This comprehensive inspection, guided by Compliance Programs 7371.001 and 7356.002, covered various systems including quality, facilities, equipment, materials, production, packaging, labeling, and laboratory controls. The primary focus was on the company’s manufacturing of tablets shipped to the U.S. market, with a limited review of terminally sterilized products not yet distributed in the U.S. Significantly, the inspection concluded with no Form FDA 483 Inspectional Observations issued, indicating no new deficiencies were identified during this review. The report also highlighted that the firm had successfully addressed all seven observations raised during a previous pre-approval inspection in August 2018. These prior issues concerned aspects like quality control unit responsibilities, facility design to prevent contamination, supplier material reliability, temperature/humidity control, completeness of master production records, yield determination, and in-process material testing procedures. All previously required corrective actions were reviewed and found to be sufficiently implemented. This outcome affirms the company's adherence to regulatory standards for drug manufacturing at the time of this inspection.

Company
Haupt Pharma Wuelfing GmbH
Inspection date
December 7, 2018
Product type
drugs
Office
Center for Veterinary Medicine
People
  • Monica Gabriela Mielke (company_representative)
  • Daniel Vosshage (company_representative)
  • Emerich Grassinger (company_representative)
  • Frank Cremer (company_representative)
  • Kerstin Eßlinger (company_representative)
View Company Profile

ID · 593d52a9-2bd2-49d6-8518-761097cd6409

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Haupt Pharma Wuelfing GmbH
  • EIR - 2017-03-17March 17, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Haupt Pharma Wuelfing GmbH
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.